NCT04441892

Low Cost QTc Meter for Long QT Syndrome Screening in Primary Care

Terminated NA Results posted Last updated 25 July 2023

What this trial tests

NA trial testing QTc Meter in Long QT Syndrome in 33 participants. Terminated before completion.

Timeline

7 February 2019

Primary endpoint
26 March 2020

26 March 2020

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	33
Start date	7 February 2019
Primary completion	26 March 2020
Estimated completion	26 March 2020
Sites	1 location across United States

Drugs / interventions tested

• QTc Meter

Conditions studied

• Long QT Syndrome — all drugs for Long QT Syndrome →

Sponsor

Mayo Clinic

Who can join

Under 5, any sex, with Long QT Syndrome. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Low Cost QTc Meter for Long QT Syndrome Screening Primary · Baseline

Number of subjects to have a successful tracing recorded with the QTc Meter in Participants with or without Long QT Syndrome between the ages of 0 and 5

Group	Value	95% CI
QTc Meter	20
QTc Meter - Healthy Controls	4

Sponsor's own description

The purpose of this study is to further develop and evaluate a diagnostic procedure suitable for use in an inexpensive diagnostic instrument suitable for screening for Long QT Syndrome (LQTS) in the primary care environment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Precision Medicine and cardiac channelopathies: when dreams meet reality.
   Gnecchi M, Sala L, Schwartz PJ. · · 2021 · cited 37× · PMID 33686390 · DOI 10.1093/eurheartj/ehab007